{"id":17531,"date":"2022-11-03T11:52:15","date_gmt":"2022-11-03T15:52:15","guid":{"rendered":"https:\/\/www.emilysentourage.org\/?page_id=17531"},"modified":"2023-12-20T05:15:53","modified_gmt":"2023-12-20T10:15:53","slug":"emilys-entourage-funds-collaborative-research-project-connecting-labs-in-the-u-s-and-the-netherlands-to-explore-cutting-edge-ace-trna-technology","status":"publish","type":"post","link":"https:\/\/www.emilysentourage.org\/tr\/emilys-entourage-funds-collaborative-research-project-connecting-labs-in-the-u-s-and-the-netherlands-to-explore-cutting-edge-ace-trna-technology\/","title":{"rendered":"Emily's Entourage, En Yeni ACE-tRNA Teknolojisini Ke\u015ffetmek \u00dczere ABD ve Hollanda'daki Laboratuvarlar\u0131 Birbirine Ba\u011flayan Ortak Ara\u015ft\u0131rma Projesini Finanse Ediyor"},"content":{"rendered":"

Utrecht \u00dcniversitesi T\u0131p Merkezi'nde Jeffrey Beekman, PhD ve Sacha Spelier'in laboratuvar\u0131nda yap\u0131lan \u00e7al\u0131\u015fmalar, Rochester \u00dcniversitesi T\u0131p Merkezi'nde John D. Lueck, PhD'nin laboratuvar\u0131nda test edilecek<\/strong><\/em><\/h3>\n

Klinik \u00f6ncesi ara\u015ft\u0131rma projesi, KF'nin sa\u00e7ma mutasyonlar\u0131n\u0131 d\u00fczeltmek \u00fczere tamamen i\u015flevsel bir kistik fibroz transmembran iletkenlik reg\u00fclat\u00f6r\u00fc (CFTR) proteini \u00fcretmek i\u00e7in ACE-tRNA teknolojisinden yararlanmay\u0131 ama\u00e7l\u0131yor<\/strong><\/em><\/h3>\n

Lower Merion, PA - 3 Kas\u0131m 2022 - <\/span>Kistik fibrozis (KF) hastalar\u0131n\u0131n son 10%'si i\u00e7in yeni tedaviler ve tedavi ara\u015ft\u0131rmalar\u0131n\u0131 h\u0131zland\u0131ran yenilik\u00e7i bir 501(c)3 vakf\u0131 olan Emily's Entourage (EE), bug\u00fcn Rochester \u00dcniversitesi T\u0131p Merkezi ve Hollanda'daki Utrecht \u00dcniversitesi T\u0131p Merkezi'ndeki iki ekibe toplam $220.000 fon sa\u011flad\u0131\u011f\u0131n\u0131 duyurdu. Ortak ara\u015ft\u0131rma projesi, KF'nin nonsense mutasyonlar\u0131na sahip ki\u015filerde tamamen i\u015flevsel bir kistik fibroz transmembran iletkenlik reg\u00fclat\u00f6r\u00fc (CFTR) proteini \u00fcretmek i\u00e7in yeni teknolojiyi kullanmay\u0131 ara\u015ft\u0131racak.<\/span><\/p>\n

\"\"<\/span>KF'li ki\u015filerin yakla\u015f\u0131k 90%'si, CFTR mutasyonlar\u0131n\u0131n i\u015flevini geri kazand\u0131ran mutasyon hedefli tedavilerden fayda g\u00f6rmektedir. Ancak, KF'li ki\u015filerin geri kalan 10%'si \u00e7ok az i\u015flevsel protein \u00fcrettikleri veya hi\u00e7 \u00fcretmedikleri i\u00e7in bu ila\u00e7lardan fayda g\u00f6rmemektedir.<\/span><\/p>\n

\"Hasta t\u00fcrevli organoidlerde CFTR sa\u00e7ma mutasyonlar\u0131n\u0131n antikodon m\u00fchendisli\u011fi ile transfer-RNA ile bask\u0131lanmas\u0131\" ba\u015fl\u0131kl\u0131 bu ortak ara\u015ft\u0131rma projesi, tam uzunlukta, tamamen i\u015flevsel CFTR proteini \u00fcretmek i\u00e7in ACE-tRNA'lar\u0131n kullan\u0131m\u0131n\u0131 ke\u015ffetmeyi ama\u00e7lamaktad\u0131r. ACE-tRNA teknolojisi \u00fczerine yap\u0131lan \u00f6nceki \u00e7al\u0131\u015fmalar umut verici sonu\u00e7lar g\u00f6stermi\u015ftir ve bu da ACE-tRNA'lar\u0131n hasta t\u00fcrevli h\u00fccre modellerinde daha fazla ara\u015ft\u0131r\u0131lmas\u0131n\u0131n art\u0131k gerekli oldu\u011funu g\u00f6stermektedir.<\/span><\/p>\n

Emily's Entourage'\u0131n Bilimsel Ba\u015f Sorumlusu PhD Chandra Ghose, \"KF'li insanlar\u0131n son 10%'sine m\u00fcmk\u00fcn olan en k\u0131sa s\u00fcrede tedaviler getirmeye odaklanm\u0131\u015f durumday\u0131z ve bu da yenilik ve i\u015fbirli\u011fi gerektiriyor\" dedi. \"Yeni nesil bilim insanlar\u0131n\u0131 KF alan\u0131na \u00e7ekmek, finansman engellerini ortadan kald\u0131rmak ve \u00e7al\u0131\u015fmalar\u0131n\u0131 desteklemek, misyonumuza m\u00fcmk\u00fcn olan en k\u0131sa s\u00fcrede ula\u015fmak i\u00e7in kritik bile\u015fenlerdir.\"<\/span><\/p>\n

Utrecht \u00dcniversitesi T\u0131p Merkezi'nden Jeffrey Beekman, PhD ve doktora \u00f6\u011frencisi Sacha Spelier'in de aralar\u0131nda bulundu\u011fu ekibi, son teknoloji \u00fcr\u00fcn\u00fc translasyonel KF biyolojisi deneylerinin geli\u015ftirilmesi ve y\u00fcr\u00fct\u00fclmesinde \u00f6nc\u00fcl\u00fck etmektedir. Rochester \u00dcniversitesi T\u0131p Merkezi'nden John D. Lueck, PhD, ACE-tRNA teknolojisinin \u00f6nc\u00fclerindendir. \u0130ki ekip, ACE-tRNA tedavisinden sonra hastadan t\u00fcretilen h\u00fccrelerde CFTR i\u015flevini karakterize etmek i\u00e7in i\u015fbirli\u011fi i\u00e7inde \u00e7al\u0131\u015facak.<\/span><\/p>\n

Jeffrey Beekman, PhD, \"Dr. Lueck'in ekibiyle \u00e7al\u0131\u015fma f\u0131rsat\u0131 bizi ger\u00e7ekten heyecanland\u0131r\u0131yor ve EE'nin bunu m\u00fcmk\u00fcn k\u0131lan c\u00f6mert deste\u011fi i\u00e7in minnettar\u0131z\" dedi. \"\u00d6nceki \u00e7al\u0131\u015fmalar, hastadan t\u00fcretilen h\u00fccrelerdeki CFTR fonksiyon \u00f6l\u00e7\u00fcmlerinin, bu h\u00fccrelerin izole edildi\u011fi ki\u015filerde bireysel hastal\u0131k \u015fiddeti veya terap\u00f6tik yan\u0131t i\u00e7in \u00f6nemli g\u00f6stergeler olabilece\u011fini g\u00f6stermi\u015ftir. Hastadan t\u00fcretilen bu h\u00fccre modellerini kullanarak ACE-tRNA'n\u0131n g\u00fcvenli\u011fini ve CFTR i\u015flevini etkili bir \u015fekilde geri y\u00fcklemek i\u00e7in ne kadar\u0131na ihtiya\u00e7 duyuldu\u011funu do\u011frulayabiliriz.\"<\/span><\/p>\n

Daha da \u00f6nemlisi, ACE-tRNA teknolojisi, di\u011fer nadir genetik hastal\u0131klar gibi sa\u00e7ma mutasyonlarla ili\u015fkili di\u011fer hastal\u0131klar i\u00e7in de \u00e7al\u0131\u015fma potansiyeline sahiptir. Bu \u00e7al\u0131\u015fmadan elde edilen sonu\u00e7lar, ACE-tRNA'lar\u0131n d\u00fcnya \u00e7ap\u0131nda sa\u00e7ma mutasyonlara sahip say\u0131s\u0131z birey i\u00e7in klini\u011fe yakla\u015ft\u0131r\u0131lmas\u0131na potansiyel olarak yard\u0131mc\u0131 olacak kritik bilgiler sa\u011flayacakt\u0131r.<\/span><\/p>\n

Emily's Entourage'\u0131n finanse etti\u011fi hibeler hakk\u0131nda daha fazla bilgi i\u00e7in <\/span>www.emilysentourage.org\/awarded-grants<\/span><\/a>.\u00a0<\/span><\/p>\n

###<\/span><\/p>\n

Emily'nin \u00c7evresi Hakk\u0131nda<\/b>
\nEmily's Entourage, KF'nin nonsense mutasyonlar\u0131na sahip olanlar da dahil olmak \u00fczere mevcut mutasyon hedefli tedavilerden fayda g\u00f6rmeyen kistik fibrozis (KF) pop\u00fclasyonunun son 10%'sindeki bireyler i\u00e7in yeni tedaviler ve bir tedavi i\u00e7in ara\u015ft\u0131rmalar\u0131 h\u0131zland\u0131ran yenilik\u00e7i bir 501(c)3't\u00fcr. Emily's Entourage 2011 y\u0131l\u0131ndan bu yana milyonlarca dolarl\u0131k ara\u015ft\u0131rma hibesi vermi\u015f, bir KF gen terapisi \u015firketi kurmu\u015f, klinik deneylere kat\u0131l\u0131m\u0131 h\u0131zland\u0131rmak i\u00e7in bir hasta kay\u0131t defteri ve klinik deney e\u015fle\u015ftirme program\u0131 geli\u015ftirmi\u015f ve d\u00fcnya \u00e7ap\u0131nda y\u00fcksek etkili ara\u015ft\u0131rma ve ila\u00e7 geli\u015ftirme \u00e7abalar\u0131na \u00f6nc\u00fcl\u00fck etmi\u015ftir. Kurulu\u015f, New York Times, STAT, CNN, People ve daha fazlas\u0131 dahil olmak \u00fczere ulusal medyada yer alm\u0131\u015ft\u0131r. Daha fazla bilgi i\u00e7in <\/span>emilysentourage.org<\/span><\/a>. <\/span><\/p>\n

Medya \u0130leti\u015fim<\/b>
\nAshling Knight<\/span>
\nPazarlama ve \u0130leti\u015fim Direkt\u00f6r\u00fc<\/span>
\nEmily'nin \u00c7evresi<\/span>
\nashling@emilysentourage.org<\/span><\/a>\u00a0<\/span><\/p>","protected":false},"excerpt":{"rendered":"

Work from the lab of Jeffrey Beekman, PhD, and Sacha Spelier at the University Medical Center Utrecht will be tested in the lab of John D. Lueck, PhD, at the University of Rochester Medical Center The pre-clinical research project aims to leverage ACE-tRNA technology to produce a fully functional cystic fibrosis transmembrane conductance regulator (CFTR)… <\/p>\n

<\/div>\n

Daha fazla bilgi edinin<\/a><\/p>","protected":false},"author":1281,"featured_media":16426,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"_acf_changed":false,"_seopress_titles_title":"Emily\u2019s Entourage Funds Collaborative Research Project, Connecting Labs in the U.S. and the Netherlands to Explore Cutting-Edge ACE-tRNA Technology","_seopress_titles_desc":"The project aims to explore the use of ACE-tRNAs to produce full-length, fully functional CFTR protein. ","_seopress_robots_index":"","_seopress_robots_follow":"","_seopress_robots_imageindex":"","_seopress_robots_snippet":"","_seopress_robots_primary_cat":"none","_seopress_robots_breadcrumbs":"","_seopress_robots_freeze_modified_date":"","_seopress_robots_custom_modified_date":"","_seopress_robots_canonical":"","_seopress_social_fb_title":"","_seopress_social_fb_desc":"","_seopress_social_fb_img":"","_seopress_social_fb_img_attachment_id":0,"_seopress_social_fb_img_width":0,"_seopress_social_fb_img_height":0,"_seopress_social_twitter_title":"","_seopress_social_twitter_desc":"","_seopress_social_twitter_img":"","_seopress_social_twitter_img_attachment_id":0,"_seopress_social_twitter_img_width":0,"_seopress_social_twitter_img_height":0,"_seopress_redirections_value":"","_seopress_redirections_enabled":"","_seopress_redirections_enabled_regex":"","_seopress_redirections_logged_status":"both","_seopress_redirections_param":"","_seopress_redirections_type":301,"_seopress_analysis_target_kw":"","_seopress_news_disabled":"","_seopress_video_disabled":"","_seopress_video":[],"_seopress_pro_schemas_manual":[{"_seopress_pro_rich_snippets_type":"none"}],"_seopress_pro_rich_snippets_disable_all":"","_seopress_pro_rich_snippets_disable":[],"_seopress_pro_schemas":[],"_monsterinsights_skip_tracking":false,"_jetpack_newsletter_access":"","_jetpack_dont_email_post_to_subs":false,"_jetpack_newsletter_tier_id":0,"_jetpack_memberships_contains_paywalled_content":false,"_jetpack_feature_clip_id":0,"_jetpack_memberships_contains_paid_content":false,"footnotes":"","jetpack_post_was_ever_published":false},"categories":[178],"tags":[],"class_list":["post-17531","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-press-releases"],"acf":[],"jetpack_sharing_enabled":true,"jetpack_featured_media_url":"https:\/\/www.emilysentourage.org\/wp-content\/uploads\/Emilys-Entourage-Logo_Website-Featured-Image.png","post_mailing_queue_ids":[],"_links":{"self":[{"href":"https:\/\/www.emilysentourage.org\/tr\/wp-json\/wp\/v2\/posts\/17531","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.emilysentourage.org\/tr\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.emilysentourage.org\/tr\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.emilysentourage.org\/tr\/wp-json\/wp\/v2\/users\/1281"}],"replies":[{"embeddable":true,"href":"https:\/\/www.emilysentourage.org\/tr\/wp-json\/wp\/v2\/comments?post=17531"}],"version-history":[{"count":5,"href":"https:\/\/www.emilysentourage.org\/tr\/wp-json\/wp\/v2\/posts\/17531\/revisions"}],"predecessor-version":[{"id":20535,"href":"https:\/\/www.emilysentourage.org\/tr\/wp-json\/wp\/v2\/posts\/17531\/revisions\/20535"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/www.emilysentourage.org\/tr\/wp-json\/wp\/v2\/media\/16426"}],"wp:attachment":[{"href":"https:\/\/www.emilysentourage.org\/tr\/wp-json\/wp\/v2\/media?parent=17531"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.emilysentourage.org\/tr\/wp-json\/wp\/v2\/categories?post=17531"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.emilysentourage.org\/tr\/wp-json\/wp\/v2\/tags?post=17531"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}